H.U. Group (MRCHF) Fair Value & Analysis
Healthcare · US · Market cap $1.1B
H.U. Group
MRCHF · US
Fair value as of: Jul 19, 2026
From 22 valuation models · updated 22 days ago
Fair value updated Jul 19, 2026, revised from $16.91 to $13.07 (−22.7%) since Jun 24, 2026. Share price −2.7% over the past month.
A solid business, but screening 36% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($16.34). The favourable scenario is already priced in.
- Solid but not exceptional quality (66/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year. As of Jul 19, 2026.
How to read this chart
60‑month range $13.09 – $30.32 · fair‑value band $9.80 – $16.34 · the $20.38 price screens above the $13.07 fair value. As of Jul 19, 2026.
Analysis
H.U. Group (MRCHF) currently trades at $20.38, while our model-based Fair Value estimate is $13.07, implying the stock looks roughly 35.9% overvalued today. The Quality Score stands at 66/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, H.U. Group generated revenue of $247B at a net margin of 2.8%. Revenue declined 0.6% year over year. It earns a return on equity of 4.9%. Net debt stands at $26.4B. Fundamentals as of Jul 19, 2026
Our scenario range runs from $9.80 (bear case) to $16.34 (bull case); at $20.38, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 27% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -48% fair-value upside, at -36%, MRCHF screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 22 models by family
Widest divergence: DCF Models ($21.85) versus Earnings-Based ($4.45). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 66 · Market factors (momentum, volatility) 34
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
H.U. Group Holdings, Inc., together with its subsidiaries, operates healthcare business in Japan, the United States, Europe, and internationally.
Full company description
H.U. Group Holdings, Inc., together with its subsidiaries, operates healthcare business in Japan, the United States, Europe, and internationally. The Lab Testing and Its Related Services segment provides general testing services to medical institutions that include esoteric testing, such as genetic and oncology testing; companion diagnostics-related tests for cancer treatment; omics analysis comprising whole genome sequencing and proteome analysis; comprehensive support for clinical trials and research, including pre-trial setup work, specimen collection and transport, measuring, result reports, and data management, as well as SaaS for general practitioners and personal health records. Its In-Vitro Diagnostics segment provides Lumipulse system products, an automated chemiluminescence enzyme immunoassay system that offers reagents; testing services for neurodegenerative diseases; and rapid diagnostics kit for infectious diseases comprising influenza and COVID-19, as well as cerebrospinal fluid reagent. This segment also develops blood-based reagents and biomarkers specifically for neurodegenerative diseases, such as Alzheimer's. The Healthcare-related Services segment offers in-house sterilization for central supply rooms in hospitals and external sterilization at sterilization centers; operating room support, endoscopy room support, medical equipment maintenance and inspection, and logistics management and transportation services; support for important tasks related to hospital administration work, including the sale of medical equipment, supplies, and consumables related to central supply rooms and operating rooms; bulk rentals of nursing care equipment, supplying equipment, including wheelchairs and nursing beds; and home medical care and nursing services. The company was formerly known as Miraca Holdings Inc. and changed its name to H.U. Group Holdings, Inc. in July 2020. H.U. Group Holdings, Inc. was incorporated in 1950 and is headquartered in Tokyo, Japan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
H.U. Group reported revenue of $249B in FY2026 versus $273B in FY2022, a compound −2.3%/yr. Reported net income was $6.9B in FY2026, compounding −30.6%/yr from FY2022.
MRCHF screens 36% overvalued. Compare with Thermo Fisher Scientific Inc →
Peer Group
Diagnostics & Research · 136 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $543.19 | $308.19 | -43% |
| Danaher Corporation DHR | $199.66 | $103.88 | -48% |
| WuXi AppTec Co 2359 | HK$160.70 | HK$125.20 | -22% |
| Lonza Group LONN | CHF 567.80 | CHF 259.80 | -54% |
| IDEXX Laboratories, Inc IDXX | $567.44 | $255.77 | -55% |
| Agilent Technologies, Inc A | $131.46 | $62.70 | -52% |
| Waters Corporation WAT | $368.98 | $121.96 | -67% |
| IQVIA Holdings IQV | $207.85 | $134.18 | -35% |
| Integrated Diagnostics Holdings IDHC | $0.0050 | $0.0053 | +5% |
| Illumina, Inc ILMN | $186.65 | $95.51 | -49% |
Compare H.U. Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is H.U. Group (MRCHF) overvalued or undervalued?
What is the fair value of MRCHF?
What is the quality score of MRCHF?
What is the revenue of H.U. Group (MRCHF)?
What is the net profit margin of MRCHF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track H.U. Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.